Group IIA phospholipase A2 content of tears in patients with atopic blepharoconjunctivitis

Peuravuori, Heikki; Kari, Osmo; Peltonen, Sirje; Aho, Valtteri V.; Saari, Jukka; Collan, Yrjö; Määttä, Marko; Saari, K. M.

doi:10.1007/s00417-004-0941-8

Cited by 20 publications

(11 citation statements)

References 15 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A plausible explanation of the low values of GIIAPLA 2 in tears of patients with ocular rosacea is increased consumption due to longstanding continuous staphylococcal stimulation. However, even this explanation is suitable only to more severe cases of ocular rosacea with dry eye symptoms in the same way as reported in ABC (Peuravuori et al 2004).…”

Section: Discussionmentioning

confidence: 89%

“…An earlier study reported slightly but not significantly decreased levels of tear lactoferrin in chronic meibomitis associated with acne rosacea (Kiratli et al 2000). Interestingly, tear GIIAPLA 2 and lysozyme levels are likewise decreased in patients with ABC (Saari & Klockars 1983; Peuravuori et al 2004) and the disorders share clinical features of chronic inflammation of the conjunctiva and lid margin.…”

Section: Discussionmentioning

confidence: 99%

“…GIIAPLA 2 is a lipolytic enzyme that is capable of killing a broad spectrum of gram‐positive bacteria (Qu & Lehrer 1998; Moreau et al 2001). We have previously studied tear content of GIIAPLA 2 in patients with atopic blepharoconjunctivitis (ABC) and found it to be lower than in controls (Peuravuori et al 2004). There are no available data on GIIAPLA 2 concentration in the tears of patients with ocular rosacea, which shares many clinical features with ABC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Group IIA phospholipase A₂ concentration of tears in patients with ocular rosacea

Kari

Aho

Peltonen

et al. 2005

Acta Ophthalmologica Scandinavica

Self Cite

View full text Add to dashboard Cite

ABSTRACT.Purpose: To determine the concentration of group IIA phospholipase A 2 (GIIAPLA 2 ) in tears of patients with ocular rosacea, and to compare it with GIIAPLA 2 concentration in tears of age-matched healthy controls. Methods: The GIIAPLA 2 concentration in tears was measured with a timeresolved fluoroimmunoassay in 21 patients with ocular rosacea (mean age 55.6±9.2 years) and in 21 normal subjects (mean age 53.4±8.2 years). Conjunctival brush cytology was carried out and eosinophils, neutrophils, lymphocytes, squamous epithelial cells, columnar epithelial cells, metaplastic changes and goblet cells were calculated separately. Results: The GIIAPLA 2 concentration in tears was statistically significantly lower in patients with ocular rosacea (31.0±18.4 mg/ml, p=0.0099) and, more specifically, in patients who had dry eye (25.8±15.1 mg/ml, p=0.0034), compared to that in normal controls. There was no correlation between the GIIAPLA 2 content of tears and the conjunctival cells collected by the brush cytology. Conclusion: The tears of patients with dry eye symptoms due to ocular rosacea have decreased GIIAPLA 2 content. The pathogenic importance of this finding is discussed.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Group IIA phospholipase A₂ concentration of tears in patients with ocular rosacea

Kari

Aho

Peltonen

et al. 2005

Acta Ophthalmologica Scandinavica

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, to our knowledge no mechanistic study has been carried out to investigate the inflammatory mediator role of sPLA2-IIa on the ocular surface, despite the concentration or activity of sPLA2-IIa in tears being reported significantly changed in patients with external inflammatory diseases, such as dry eye disease (Aho et al, 2002), post PRK laser surgery (Aho et al, 2003), chronic blepharitis (Song et al, 1999), ocular rosacea (Kari et al, 2005) and atopic blepharoconjunctivitis (Peuravuori et al, 2004). These clinical documentations imply that there may be an association of tear sPLA2-IIa with inflammatory diseases of the ocular surface.…”

Section: Introductionmentioning

confidence: 99%

sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised

Chen

Wei

et al. 2009

Experimental Eye Research

View full text Add to dashboard Cite

sPLA2-IIa is an enzyme at high concentration in tears that has been known as an innate barrier of the ocular surface against microbial infection. sPLA2-IIa and other enzymes in the same protein family are known to hydrolyze fatty acids resulting in the generation of free arachidonic acid (AA) and lysophospholipids, which are the precursors of pro-inflammatory lipid mediators, such as PGE2. sPLA2-IIa has been shown to be an inflammatory mediator in non-ocular inflammatory diseases such as rheumatoid arthritis (RA). It was also found to be increased in the tears of the patients with dry eye disease, chronic blepharitis and contact lens intolerance. However, the role of sPLA2-IIa in chronic ocular surface inflammation has yet to be determined. In the current study, we examined the potential role of sPLA2-IIa in inflammation of ocular surface diseases. Our results show that the activity of sPLA2-IIa was significantly increased in tears from dry eye disease patients compared with that from normal subjects. Also, sPLA2-IIa stimulated the production of PGE2 in ocular surface epithelial cell cultures. The stimulating effect was markedly enhanced when the cells or tissues were pre-compromised with TNF-α, IL-1β or desiccation. Furthermore, sPLA2-IIa stimulated inflammatory cytokine production in the ocular surface epithelial cell cultures in vitro. To our knowledge, this is the first report regarding the role of sPLA2-IIa as an inflammatory mediator in ocular surface inflammation. These findings indicate that sPLA2-IIa may play an important role in chronic ocular surface inflammation, especially when the ocular surface is compromised.

show abstract

“…Dermatite atópica (DA) é uma doença inflamatória crônica da pele, que ocorre mais comumente entre a infância e a adolescência e resulta em defeitos na barreira de proteção da pele, do sistema imunológico e respostas exacerbadas a antígenos microbianos e alérgenos (1)(2)(3)(4)(5)(6)(7)(8) .…”

Section: Resumo Introduçãounclassified

Dermatoceratoconjuntivite atópica em pacientes do Ambulatório de Dermatologia Infanto-Juvenil em centro de referência

Moscovici¹,

Cesar²,

Nishiwaki-Dantas³

et al. 2009

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Group IIA phospholipase A2 content of tears in patients with atopic blepharoconjunctivitis

Abstract: The results indicate that in patients with ABC the GIIAPLA(2) content of tears was decreased, without any dependence on the quantity of different conjunctival cells.

Cited by 20 publications

References 15 publications

Group IIA phospholipase A₂ concentration of tears in patients with ocular rosacea

Group IIA phospholipase A₂ concentration of tears in patients with ocular rosacea

sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised

Dermatoceratoconjuntivite atópica em pacientes do Ambulatório de Dermatologia Infanto-Juvenil em centro de referência

Contact Info

Product

Resources

About

Group IIA phospholipase A2 content of tears in patients with atopic blepharoconjunctivitis

Abstract: The results indicate that in patients with ABC the GIIAPLA(2) content of tears was decreased, without any dependence on the quantity of different conjunctival cells.

Cited by 20 publications

References 15 publications

Group IIA phospholipase A2 concentration of tears in patients with ocular rosacea

Group IIA phospholipase A2 concentration of tears in patients with ocular rosacea

sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised

Dermatoceratoconjuntivite atópica em pacientes do Ambulatório de Dermatologia Infanto-Juvenil em centro de referência

Contact Info

Product

Resources

About

Group IIA phospholipase A₂ concentration of tears in patients with ocular rosacea

Group IIA phospholipase A₂ concentration of tears in patients with ocular rosacea